Published in World J Clin Oncol on June 10, 2017
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Hepatocellular carcinoma. Lancet (2012) 18.09
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
STATs in oncogenesis. Oncogene (2000) 8.60
Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology (2004) 8.36
Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology (2011) 4.60
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol (2013) 4.28
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell (2003) 3.66
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem (2005) 3.08
Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol (2012) 2.94
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol (2006) 2.25
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist (2009) 2.23
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol (2011) 2.12
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int (2011) 1.84
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA (2014) 1.80
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol (2010) 1.77
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist (2012) 1.76
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol (2009) 1.75
Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol (2004) 1.70
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol (2015) 1.66
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer (2011) 1.59
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res (2010) 1.50
Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci (2012) 1.45
Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci (2008) 1.44
Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation. Transpl Int (2013) 1.44
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res (2010) 1.43
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract (2013) 1.41
A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities. Mol Cancer Ther (2008) 1.30
Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene (2001) 1.29
Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int (2013) 1.29
Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther (2008) 1.24
Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res (2007) 1.19
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther (2011) 1.17
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl (2012) 1.16
Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS One (2014) 1.15
Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev (2009) 1.13
Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer (2012) 1.13
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer (2013) 1.12
Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant (2006) 1.12
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest Cancer Res (2011) 1.10
Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Hepatology (2013) 1.10
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol (2010) 1.05
SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J Cell Biochem (2003) 1.04
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol (2012) 1.03
By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice. Oncotarget (2015) 1.03
Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One (2014) 0.98
2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Cancer Lett (2014) 0.96
Radiotherapy and hepatocellular carcinoma: update and review of the literature. Eur Rev Med Pharmacol Sci (2012) 0.96
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol (2013) 0.96
Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR Am J Roentgenol (2008) 0.94
Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression. Oncogene (2003) 0.94
Protective effect of food additives on aflatoxin-induced mutagenicity and hepatocarcinogenicity. Cancer Lett (1997) 0.94
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin Cancer Res (2014) 0.93
Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways. Anticancer Res (2014) 0.91
Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology (2010) 0.91
Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant (2013) 0.91
Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol (2013) 0.90
Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol (2016) 0.88
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. J Surg Res (2013) 0.86
Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study. Ann Surg Oncol (2013) 0.86
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia (2013) 0.86
Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. World J Gastroenterol (2014) 0.85
Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatol Int (2016) 0.85
Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience. Transplant Proc (2010) 0.84
High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Transpl Int (2012) 0.84
Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy? J Gastrointest Cancer (2010) 0.84
The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol (2015) 0.82
Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells. DNA Cell Biol (2014) 0.82
A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. Biochem Biophys Res Commun (2015) 0.81
Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Rev Anticancer Ther (2014) 0.80
Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? Expert Rev Anticancer Ther (2016) 0.79
Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evid (2014) 0.78
A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Cancer Lett (2015) 0.78
Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report. Transplant Proc (2016) 0.78
Cytotoxic effects of 2-methoxyestradiol in the hepatocellular carcinoma cell line HepG2. Pharmacology (2009) 0.78
A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3. Cancer Lett (2014) 0.78
Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. Hepatology (2016) 0.78
Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. Liver Cancer (2016) 0.78
FH535 inhibits the proliferation of HepG2 cells via downregulation of the Wnt/β-catenin signaling pathway. Mol Med Rep (2014) 0.77
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? Transplant Proc (2012) 0.77
Sorafenib use in the transplant setting. Liver Transpl (2014) 0.77
Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? Expert Rev Anticancer Ther (2012) 0.76
Hepatocellular carcinoma: Will novel targeted drugs really impact the next future? World J Gastroenterol (2016) 0.76
Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review. Exp Clin Transplant (2016) 0.75
Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation. Prog Transplant (2016) 0.75
Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. J Hepatocell Carcinoma (2016) 0.75